Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.72 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.56 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.56 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.56 |
| ▸ | JAK1 | P23458 | 2/20 | 0.54 |
| ▸ | TYK2 | P29597 | 2/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141767 | 0.93 | JAK2 (0.62) | JAK2TLR9TLR8TLR7JAK1 | |
| SCHEMBL147444 | 0.84 | JAK2 (1.00) | JAK2TLR9TLR8TLR7JAK1 | |
| SCHEMBL140715 | 0.84 | JAK2 (0.83) | JAK2TLR9TLR8TLR7JAK1 | |
| SCHEMBL178649 | 0.83 | JAK2 (0.64) | JAK2TLR8TLR7JAK1TYK2 | |
| SCHEMBL143618 | 0.83 | JAK2 (0.87) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL138605 | 0.83 | JAK2 (0.66) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL178699 | 0.80 | JAK2 (1.00) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL142102 | 0.80 | JAK2 (0.63) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL140658 | 0.78 | JAK2 (0.59) | JAK2TLR8TLR7JAK1TYK2 | |
| SCHEMBL144648 | 0.78 | JAK2 (0.65) | JAK2JAK1TYK2JAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| WO-2010080474-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885TLR9 3163/4885TLR8 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.